Efficacy And Safety Of Cd19 Chimeric Antigen Receptor (Car) T Cell Therapy For B-Cell Acute Lymphocytic Leukemia (B-Cell All) In A Large Cohort Including Patients With Extramedullary Disease(Emd), High Leukemia Burden, Bcr-Abl (+) Mutation,Tp53 Mutation, And Post-Transplant Relapse

Introduction: CD19 CAR-T therapy is effective for B-cell ALL. However, whether patients (pts) with EMD, High Leukemia Burden (HLB), TP53 mutation, BCR-ABL (+) mutation, or post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) relapse can benefit from the treatment remains to be investigated. Here we show the efficacy and safety of CD 19 CAR-T therapy for these subgroups.